MACROGENICS, INC. Construction in Progress, Gross
MACROGENICS, INC. (MGNX) had Construction in Progress, Gross of $371.00 thousand as of 2025-12-31, per its 10-K filed 2026-03-09.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent › Property, Plant, and Equipment, after Accumulated Depreciation, Depletion, and Amortization › Property, Plant, and Equipment, before Accumulated Depreciation, Depletion, and Amortization
us-gaap:ConstructionInProgressGross · last filed 2026-03-09
- 2025-12-31: Construction in Progress, Gross $371.00K.
- 2024-12-31: Construction in Progress, Gross $1.22M.
- 2023-12-31: Construction in Progress, Gross $1.11M.
- 2022-12-31: Construction in Progress, Gross $356.00K.
| Period end | Construction in Progress, Gross |
|---|---|
| 2025-12-31 | $371.00K 10-K · filed 2026-03-09 |
| 2024-12-31 | $1.22M 10-K · filed 2026-03-09 |
| 2023-12-31 | $1.11M 10-K · filed 2025-03-20 |
| 2022-12-31 | $356.00K 10-K · filed 2024-03-07 |
| 2021-12-31 | $630.00K 10-K · filed 2023-03-15 |
| 2020-12-31 | $2.02M 10-K · filed 2022-02-24 |
| 2019-12-31 | $187.00K 10-K · filed 2021-02-25 |
| 2018-12-31 | $218.00K 10-K · filed 2020-02-25 |
| 2017-12-31 | $32.80M 10-K · filed 2019-02-26 |
| 2016-12-31 | $0.00 10-K · filed 2018-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |